Sera Prognostics, Inc. Class A (SERA)

Over the past six months, Sera Prognostics' stock price has declined by 29.96%. Key events include Q3 2025 financial results with a net loss of $7.8 million and $102.4 million in cash, Q4 and full-year 2025 results with a net loss of $7.9 million and $31.9 million respectively, and Q1 2026 results with a net loss of $8.4 million and revenue of $14,000. Insider activity has shown a trend of selling, with insiders selling $0.1 million worth of shares.

There is no indication of significant demand seasonality for Sera Prognostics' products and services, as pregnancy and associated diagnostic needs generally occur throughout the year.

Sera Prognostics, Inc. is a women's health diagnostic company utilizing a proteomics and bioinformatics platform to develop blood-based biomarker tests and predictive analytic products. Operating in the Healthcare sector, its flagship product is the PreTRM test, a non-invasive blood test predicting the risk of spontaneous premature delivery. The company is also developing a pipeline of tests for various pregnancy-related conditions.

Sera Prognostics is headquartered in Salt Lake City, Utah, and primarily focuses on the United States market. The company is expanding its European evidence base and plans to submit its CE Marking dossier, indicating potential commercialization in Europe.

Sera Prognostics has focused on enhancing its brand reputation through scientific validation and outreach. The publication of the PRIME study demonstrated the PreTRM test's efficacy and cost-saving benefits. The company has expanded its European evidence base and is actively engaging in consumer and provider outreach to boost brand awareness.

Sera Prognostics has a mixed ownership structure including institutional, retail, and individual investors. Institutional investors own between 7.55% and 14.62% of the stock, insiders own 7.75%, and public companies and individual investors own 77.63%. Major institutional owners include Baker Bros. Advisors LP, Baker Brothers Life Sciences, L.P., and Whetstone Capital Advisors, LLC. Felix Baker owns the most shares.